Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaxis Ltd ( (AU:SNT) ) just unveiled an announcement.
Syntara Limited, a company involved in the healthcare sector, has announced the proposed issuance of performance rights to its Chief Executive Officer as part of its employee incentive scheme. This move, pending shareholder approval at the annual general meeting, aims to reward, incentivize, and retain senior managers and key employees. The performance rights, which are unlisted and have no grant or exercise price, will vest in two equal parts in 2027 and 2028, with restrictions on trading until approved by the Syntara Board. This initiative underscores Syntara’s commitment to aligning executive compensation with long-term company performance.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Average Trading Volume: 9,860,498
Technical Sentiment Signal: Hold
Current Market Cap: A$97.65M
For a thorough assessment of SNT stock, go to TipRanks’ Stock Analysis page.